Search - tctmd.com

Displaying 1 - 15 of 15

Sort: Relevancy | Date

News Conference News AHA 2020

Latest Post-DES Drug Trial Tests Aspirin Monotherapy After 1 Month of DAPT

Shelley Wood

November 15, 2020

News Conference News AHA 2020

Clopidogrel Should Remain Antiplatelet of Choice in Elective PCI: ALPHEUS

Michael O'Riordan

November 14, 2020

News Daily News

Fewer MIs With Prasugrel Than Ticagrelor in STEMI Patients: ISAR-REACT 5

Michael O'Riordan

November 03, 2020

News Conference News TCT 2020

Shorter DAPT Succeeds in Xience-Treated Patients at High Bleeding Risk

Caitlin E. Cox

October 15, 2020

News Daily News

Features of Complex CAD Carry Progressive Risk in PCI, Registry Confirms

Caitlin E. Cox

October 08, 2020

News Daily News

‘Aspirin-Free’ Antiplatelet Strategy Feasible After PCI, Pilot Study Suggests

Michael O'Riordan

September 18, 2020

News Daily News

‘Speaking the Same Language’: New Guidance for Trials of Patients at High Bleeding Risk

Michael O'Riordan

September 16, 2020

News Daily News

Analysis Supports Short DAPT Followed by P2Y12 Inhibitor Monotherapy After DES PCI

L.A. McKeown

August 10, 2020

News Conference News EuroPCR 2020

Tirofiban Provides Better Platelet Inhibition Than Cangrelor in STEMI Patients

Michael O'Riordan

June 30, 2020

News Daily News

No Long-term Mortality Risk for Paclitaxel-Based Peripheral Devices: Medicare Advantage Cohort

L.A. McKeown

June 29, 2020

News Daily News

Stent Thrombosis May Be Presenting Feature of COVID-19

Yael L. Maxwell

June 08, 2020

News Daily News

Clopidogrel Holds Advantage in Older NTSE ACS Patients: POPular AGE Published

Michael O'Riordan

April 27, 2020

News Conference News ACC 2020

TICO: Ticagrelor Monotherapy After 3 Months of DAPT Curbs Bleeding in Stented ACS Patients

Todd Neale

March 31, 2020

News Daily News

Potent Antithrombotic Therapy Cuts Spontaneous MI After PCI for ACS

Yael L. Maxwell

March 10, 2020

News Daily News

No Fewer MACE With Ticagrelor vs Clopidogrel in ACS Patients After PCI: Registry

Todd Neale

January 15, 2020

Advertisement

Latest Post-DES Drug Trial Tests Aspirin Monotherapy After 1 Month of DAPT

Clopidogrel Should Remain Antiplatelet of Choice in Elective PCI: ALPHEUS

Fewer MIs With Prasugrel Than Ticagrelor in STEMI Patients: ISAR-REACT 5

Shorter DAPT Succeeds in Xience-Treated Patients at High Bleeding Risk

Features of Complex CAD Carry Progressive Risk in PCI, Registry Confirms

‘Aspirin-Free’ Antiplatelet Strategy Feasible After PCI, Pilot Study Suggests

‘Speaking the Same Language’: New Guidance for Trials of Patients at High Bleeding Risk

Analysis Supports Short DAPT Followed by P2Y12 Inhibitor Monotherapy After DES PCI

Tirofiban Provides Better Platelet Inhibition Than Cangrelor in STEMI Patients

No Long-term Mortality Risk for Paclitaxel-Based Peripheral Devices: Medicare Advantage Cohort

Stent Thrombosis May Be Presenting Feature of COVID-19

Clopidogrel Holds Advantage in Older NTSE ACS Patients: POPular AGE Published

TICO: Ticagrelor Monotherapy After 3 Months of DAPT Curbs Bleeding in Stented ACS Patients

Potent Antithrombotic Therapy Cuts Spontaneous MI After PCI for ACS

No Fewer MACE With Ticagrelor vs Clopidogrel in ACS Patients After PCI: Registry

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content